RDDA Financial Statements From 2010 to 2024
| RDDA Stock | EUR 13.20 0.10 0.75% |
Check Dr Reddys financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dr Reddys' main balance sheet or income statement drivers, such as , as well as many indicators such as . RDDA financial statements analysis is a perfect complement when working with Dr Reddys Valuation or Volatility modules.
RDDA |
Dr Reddys Laboratories Company Return On Equity Analysis
Dr Reddys' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Dr Reddys Return On Equity | 0.18 |
Most of Dr Reddys' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Dr Reddys Laboratories has a Return On Equity of 0.1772. This is 100.74% lower than that of the Healthcare sector and 49.37% lower than that of the Drug Manufacturers - Specialty & Generic industry. The return on equity for all Germany stocks is 157.16% lower than that of the firm.
Dr Reddys Laboratories Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Dr Reddys's current stock value. Our valuation model uses many indicators to compare Dr Reddys value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Dr Reddys competition to find correlations between indicators driving Dr Reddys's intrinsic value. More Info.Dr Reddys Laboratories is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.54 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Dr Reddys Laboratories is roughly 1.87 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Dr Reddys' earnings, one of the primary drivers of an investment's value.About Dr Reddys Financial Statements
Dr Reddys stakeholders use historical fundamental indicators, such as Dr Reddys' revenue or net income, to determine how well the company is positioned to perform in the future. Although Dr Reddys investors may analyze each financial statement separately, they are all interrelated. For example, changes in Dr Reddys' assets and liabilities are reflected in the revenues and expenses on Dr Reddys' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Dr Reddys Laboratories. Please read more on our technical analysis and fundamental analysis pages.
Reddys Laboratories Limited operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. DR REDDYS operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 21966 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in RDDA Stock
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out the analysis of Dr Reddys Correlation against competitors. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.